Pedro Modrego

Dr. Pedro Modrego

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2014 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
FAFrancisco J. Ascaso
Francisco J. Ascaso
NCNancy Cruz
Nancy Cruz
PMPedro Modrego
Pedro Modrego
Raul López AntónRaul López Antón
Raul López Antón
JSJavier Santabárbara
Javier Santabárbara
JCJosé A. Cristóbal
José A. Cristóbal

10 September 2010 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
PMPedro Modrego
Pedro Modrego
Depression is a comorbid condition in Alzheimer's disease (AD) with negative consequences in patients and caregivers. Pathophysiology and optimal treatment are matters to be elucidated. A search of articles dealing with depression in AD was conducted

1 December 2005 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
PMPedro Modrego
Pedro Modrego
JMJ. Mojonero
J. Mojonero
MSM. Serrano
M. Serrano
NFN. Fayed
N. Fayed

23 February 2010 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
PMPedro Modrego
Pedro Modrego
NFN. Fayed
N. Fayed
JEJ. M. Errea
J. M. Errea
CRC. Rios
C. Rios
MPM. A. Pina
M. A. Pina
MSM. Sarasa
M. Sarasa

23 February 2011 in BMJ Open
Verified
Journal Article
Open access
PDF file
PMPedro Modrego
Pedro Modrego
NFNicolas Fayed
Nicolas Fayed
MSManuel Sarasa
Manuel Sarasa
Background: Mild cognitive impairment (MCI) of an amnestic type is a common condition in older people and highly predictive of Alzheimer's disease (AD). To date, there is no clear consensus regarding the best antecedent biomarker to predict early conversion to AD. Objective: The aim of the study is to demonstrate that 1 H magnetic resonance spectroscopy (MRS) of the brain in MCI patients may predict early conversion to dementia within the 2-year period after baseline assessment. Methods: A cohort of patients fulfilling the criteria of amnestic MCI were enrolled consecutively. At baseline the patients underwent neuropsychological examination, standard blood tests and APOE genotype. 1 H-MRS (1.5 T) of the brain was carried out by exploring two areas: the posteromedial bilateral parietal lobe and left medial occipital lobe. The patients were followed up to detect conversion to probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association group criteria. Results: After a 2-year follow-up, 27 (38%) patients converted to AD. The mean N-acetyl-aspartate/creatine (NAA/Cr) ratio in the posteromedial bilateral parietal cortex was 1.38 in converters versus 1.49 in non-converters (p<0.0001). An NAA/Cr ratio equal to or lower than 1.43 in this area predicted conversion to probable AD at 74.1% sensitivity and 83.7% specificity (area under the curve: 0.84; 95% CI 0.73 to 0.92). The cross-validated accuracy of classification was 82%, which reaches 85% when the APOE4 genotype and memory test are included in the analysis. In the left medial occipital lobe, the predictive value was somewhat lower with 85.2% sensitivity and 61.4% specificity (area under the curve: 0.8; 95% CI 0.69 to 0.89). Neither the APOE4 genotype nor leuco-araiosis was predictive of conversion to dementia. Conclusion: MRS is a valuable biomarker to predict early conversion to dementia in patients with amnestic MCI.

1 February 2011 in Academic Radiology
Verified
Journal Article
Closed access
PMPedro Modrego
Pedro Modrego
NFNicolás Fayed
Nicolás Fayed
JAJorge Artal
Jorge Artal
SOSalvador Olmos
Salvador Olmos